Akebia Therapeutics

179 articles with Akebia Therapeutics

• Ex-Akebia Director Re-arrested After Insider Trading Prosecutors Call Him 'Unhinged'

  9/26/2017

• Akebia Hits A New High As Kidney Disease Drug Meets Mid-Stage Trial Goals

  9/26/2017

• Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  9/8/2017

• Akebia Announces Second Quarter 2017 Financial Results

  8/9/2017

• Akebia Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

  8/7/2017

• Akebia Announces Closing Of Public Offering Of Common Stock And Exercise Of Option By Underwriters

  7/6/2017

• Akebia Announces Proposed Public Offering Of Common Stock

  6/29/2017

• Akebia Announces Pricing Of Public Offering Of Common Stock

  6/29/2017

• Akebia To Host Analyst And Investor Day On June 27, 2017

  6/20/2017

• Akebia Prevails In Two Additional European Patent Disputes

  6/5/2017

• Akebia Names Rita Jain, M.D. As Chief Medical Officer

  5/25/2017

• Akebia Initiates Phase II FO2RWARD Study Of Vadadustat In Dialysis Patients With Anemia Related To Chronic Kidney Disease Hyporesponsive To Treatment With Erythropoiesis-Stimulating Agents

  5/24/2017

• Akebia, Vifor Pharma Strike $50 Million Exclusive Anemia Drug Pact

  5/16/2017

• Akebia And Vifor Pharma Announce Exclusive License Agreement To Provide Vadadustat To Fresenius Medical Care In The U.S. Upon Vifor Pharma Approval

  5/16/2017

• Akebia Announces First Quarter 2017 Financial Results

  5/10/2017

• Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  5/5/2017

• Why Akebia, Even With Otsuka Pharma's Big Deal, May Need To Be Acquired

  4/27/2017

• Otsuka Pharma Believes in Akebia, Commits Another $865 Million to Expand Anemia Deal

  4/26/2017

• Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  4/7/2017

• Akebia Announces Publication Of Phase IIa Results For Vadadustat In Patients With Anemia Related To Chronic Kidney Disease

  3/28/2017